Comparative Pharmacology
Head-to-head clinical analysis: NORGESTIMATE ETHINYL ESTRADIOL versus OGEN 2 5.
Peer-Reviewed Evidence
Head-to-head clinical analysis: NORGESTIMATE ETHINYL ESTRADIOL versus OGEN 2 5.
NORGESTIMATE; ETHINYL ESTRADIOL vs OGEN 2.5
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Combination oral contraceptive containing norgestimate (a progestin) and ethinyl estradiol (an estrogen). The primary mechanism is suppression of gonadotropins (FSH and LH) via negative feedback on the hypothalamic-pituitary-ovarian axis, preventing ovulation. Additional effects include thickening cervical mucus (inhibiting sperm penetration) and altering endometrial receptivity.
Estrogen replacement therapy; binds to estrogen receptors, leading to activation of estrogen-responsive genes and physiological effects mimicking endogenous estrogens.
Oral, one tablet daily at the same time for 21 days, followed by 7 placebo tablets.
0.625 mg orally once daily (estropipate 0.75 mg equivalent), cyclic or continuous.
None Documented
None Documented
Norgestimate: terminal half-life of norelgestromin (active metabolite) is 27.6 ± 7.8 hours; ethinyl estradiol: terminal half-life is 17.5 ± 6.3 hours. Steady state achieved within 14 days.
10-24 hours; terminal half-life may be prolonged in hepatic impairment.
Norgestimate metabolites are primarily excreted via urine (60-80%) and feces (35-49%) as glucuronide and sulfate conjugates; ethinyl estradiol is excreted in urine (40%) and feces (60%) as conjugates.
Primarily renal as sulfate and glucuronide conjugates; less than 10% excreted unchanged.
Category D/X
Category C
Progestin + Estrogen
Estrogen